Glaxo wins US approval for drug to treat severe asthma
WASHINGTON - The Food and Drug Administration has approved an injectable drug from GlaxoSmithKline PLC to treat severe asthma attacks.
The agency on Wednesday cleared Nucala for patients 12 years and older who cannot control their asthma with more conventional drug options.
According to federal figures, more than 22 million people in the U.S. have asthma, leading to more than 400,000 hospitalizations each year.
Nucala is injected every four weeks by a health care professional in the arm, thigh or abdomen. The genetically engineered antibody is grown in cells from Chinese hamsters and works by reducing levels of white blood cells that contribute to asthma.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
As Galligan withdraws from search, committee set to unveil candidates for LSU...
EBR school system cancels plan to return in July, will offer alternatives...
Tom Galligan, Interim LSU president, withdraws from consideration for permanent job
Tuesday's Health Report
INVESTIGATIVE UNIT: Former White Castle mayor arrested for alleged crimes while in...
Legendary Parkview coach Kenny Guillot passes away at 76
Southern Wins Third Straight Bayou Classic
White squad edges Purple in LSU Spring game
'We have a plan': Coach O quiet on how Title IX scandal...
Southeastern regains sole possession of first place in Southland standings with win...